JP2020515644A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515644A5 JP2020515644A5 JP2020503100A JP2020503100A JP2020515644A5 JP 2020515644 A5 JP2020515644 A5 JP 2020515644A5 JP 2020503100 A JP2020503100 A JP 2020503100A JP 2020503100 A JP2020503100 A JP 2020503100A JP 2020515644 A5 JP2020515644 A5 JP 2020515644A5
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- mrna
- utr
- residues
- systems
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17164257 | 2017-03-31 | ||
| EP17164257.2 | 2017-03-31 | ||
| EP17200162 | 2017-11-06 | ||
| EP17200162.0 | 2017-11-06 | ||
| PCT/EP2018/058036 WO2018178215A1 (en) | 2017-03-31 | 2018-03-29 | Prevention and treatment of non-melanoma skin cancer (nmsc) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515644A JP2020515644A (ja) | 2020-05-28 |
| JP2020515644A5 true JP2020515644A5 (https=) | 2021-04-15 |
| JP7264867B2 JP7264867B2 (ja) | 2023-04-25 |
Family
ID=61763994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503100A Active JP7264867B2 (ja) | 2017-03-31 | 2018-03-29 | 非メラノーマ皮膚癌（ｎｍｓｃ）の予防および治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200038487A1 (https=) |
| EP (2) | EP4019037A1 (https=) |
| JP (1) | JP7264867B2 (https=) |
| KR (1) | KR20190133216A (https=) |
| CN (1) | CN110636854A (https=) |
| AU (1) | AU2018246292A1 (https=) |
| CA (1) | CA3057768A1 (https=) |
| WO (1) | WO2018178215A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101987591B1 (ko) * | 2018-08-06 | 2019-06-10 | 국립해양생물자원관 | 인게놀 메부테이트에 특이적으로 결합하는 핵산 앱타머 및 그 용도 |
| WO2020227625A1 (en) | 2019-05-08 | 2020-11-12 | Laura Hansen | 14-3-3 targeting peptides for cancer treatment |
| US11685766B2 (en) | 2019-05-08 | 2023-06-27 | Creighton University | 14-3-3 targeting peptides for cancer treatment |
| NL2025475B1 (en) * | 2020-04-30 | 2021-11-09 | Ribopro B V | Rna molecules with decreased immunogenicity and methods for reducing rna immunogenicity |
| CN115887495A (zh) * | 2022-07-11 | 2023-04-04 | 上海默多赛生物科技有限公司 | 化学修饰的mRNA转染的皮片或皮瓣及其促进创面愈合的用途 |
| CN116785501A (zh) * | 2022-08-04 | 2023-09-22 | 上海交通大学医学院附属上海儿童医学中心 | 促进心脏组织修复的modRNA转染改造的细胞及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028422A (en) * | 1986-05-27 | 1991-07-02 | Schering Corporation | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
| CA1295243C (en) * | 1986-05-27 | 1992-02-04 | Daniel J. Tanner | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
| US5002764A (en) * | 1986-08-12 | 1991-03-26 | Schering Corporation | Treatment of actinic keratoses with alpha2 interferon |
| EP0351974A1 (en) | 1988-07-05 | 1990-01-24 | Schering Corporation | Treatment of genital warts with a combination of podophyllin and recombinant DNA human alpha interferon |
| US4959210A (en) | 1988-11-01 | 1990-09-25 | Schering Corporation | Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon |
| BR9712362A (pt) * | 1996-10-18 | 1999-08-31 | Canji Inc | Métodos e composições para distribuição e expressão de ácidos nucléicos de alfa-interferon |
| CA2323604A1 (en) * | 1998-03-19 | 1999-09-23 | Valentis, Inc. | Interferon alpha plasmids and delivery systems, and methods of making and using the same |
| RU2262510C9 (ru) | 1999-05-19 | 2006-04-20 | Лексиген Фармасьютикэлс Корп. | Слитый белок, обладающий биологической активностью интерферона-альфа, димерный слитый белок, фармацевтическая композиция, их содержащая, молекула днк (варианты) и способ адресования интерферона-альфа в ткани печени |
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| ES2302402B1 (es) | 2005-06-16 | 2009-05-08 | Proyecto De Biomedicina Cima, S.L. | Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. |
| WO2009030464A2 (de) | 2007-09-08 | 2009-03-12 | Bayer Schering Pharma Aktiengesellschaft | HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI) |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| WO2013143555A1 (en) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2013151665A2 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| RS57739B1 (sr) | 2013-03-14 | 2018-12-31 | Translate Bio Inc | Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| EP3099801B1 (en) | 2014-01-31 | 2020-03-18 | Factor Bioscience Inc. | Synthetic rna for use in the treatment of dystrophic epidermolysis bullosa |
| CA2976376A1 (en) * | 2015-02-13 | 2016-08-18 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| CA2990881C (en) | 2015-06-30 | 2024-02-20 | Ethris Gmbh | Utrs increasing the translation efficiency of rna molecules |
-
2018
- 2018-03-29 CA CA3057768A patent/CA3057768A1/en active Pending
- 2018-03-29 JP JP2020503100A patent/JP7264867B2/ja active Active
- 2018-03-29 AU AU2018246292A patent/AU2018246292A1/en not_active Abandoned
- 2018-03-29 US US16/499,683 patent/US20200038487A1/en not_active Abandoned
- 2018-03-29 EP EP22151267.6A patent/EP4019037A1/en active Pending
- 2018-03-29 EP EP18712919.2A patent/EP3600379B1/en active Active
- 2018-03-29 CN CN201880028512.5A patent/CN110636854A/zh active Pending
- 2018-03-29 WO PCT/EP2018/058036 patent/WO2018178215A1/en not_active Ceased
- 2018-03-29 KR KR1020197031641A patent/KR20190133216A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515644A5 (https=) | ||
| JP2020529208A5 (https=) | ||
| Zeng et al. | Formulation and delivery technologies for mRNA vaccines | |
| JP2018516983A5 (https=) | ||
| KR102432434B1 (ko) | Rna 투여용 제형 | |
| US8309531B2 (en) | Administration of interferon for prophylaxis against or treatment of pathogenic infection | |
| FI4017871T3 (fi) | Alfa-sarkoglykaaniin liittyvä adeno-assosioidun virusvektorin antaminen ja lihasdystrofian hoito | |
| JP2023522249A5 (https=) | ||
| Neshat et al. | Gene delivery for immunoengineering | |
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| KR100817024B1 (ko) | 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물 | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| JP2015513897A5 (https=) | ||
| ES2682056B1 (es) | Material hibrido poroso organico - inorganico, metodo de obtencion y usos | |
| HRP20151238T1 (hr) | Mutanti frataksina | |
| ES2718174T3 (es) | Polvo de alcohol polivinílico y métodos para producir el mismo | |
| Yihunie et al. | Recent advances in messenger ribonucleic acid (mRNA) vaccines and their delivery systems: a review | |
| JP2017529326A5 (https=) | ||
| JP5439189B2 (ja) | 組換えヒトインターフェロン様タンパク質及びそれをエンコードするポリヌクレオチド | |
| EA201100809A1 (ru) | НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ, ВЫСОКООЧИЩЕННЫЙ, СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА АЛЬФА С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ | |
| Huang et al. | Advances in development of mRNA-based therapeutics | |
| KR20190133216A (ko) | 비흑색종 피부암(nmsc)의 예방 및 치료 | |
| Copur | Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy. | |
| Tevz et al. | Controlled systemic release of interleukin‐12 after gene electrotransfer to muscle for cancer gene therapy alone or in combination with ionizing radiation in murine sarcomas | |
| Vasukutty et al. | Navigating latency-inducing viral infections: therapeutic targeting and nanoparticle utilization |